Biologics

Target-specific treatment of systemic and cutaneous autoimmune diseases

Siba P Raychaudhuri, Smriti Raychaudhuri

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Biologics are becoming important in the treatment of systemic and cutaneous autoimmune diseases. They are designed to target specific components of immune system. As the new drugs are capable of targeting proteins in a more specific fashion, yet have lower risks of systemic side-effects, they have considerable advantages over the older immunomodulators. The development of TNF-alpha blockers in the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis have been major breakthroughs. Likewise, B-cell depletion has proved to be equally revolutionary for the treatment of lupus, pemphigus, certain vasculitides etc. But all said and done, the development of these molecules and their clinical usage are still at evolving stages. Consensus needs be formed to further categorize the clinical profiles of the patients in whom biologics are to be used in the future, given that the long-term safety profiles of these agents are very much unknown at present.

Original languageEnglish (US)
Pages (from-to)100-109
Number of pages10
JournalIndian Journal of Dermatology
Volume54
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Biological Products
Skin Diseases
Autoimmune Diseases
Psoriatic Arthritis
Pemphigus
Ankylosing Spondylitis
Immunologic Factors
Drug Delivery Systems
Vasculitis
Psoriasis
Crohn Disease
Immune System
Rheumatoid Arthritis
B-Lymphocytes
Therapeutics
Tumor Necrosis Factor-alpha
Safety
Proteins

Keywords

  • Anti-cytokines
  • B-Lymphocyte
  • Biologics
  • Immunonodulation
  • TCR

ASJC Scopus subject areas

  • Dermatology

Cite this

Biologics : Target-specific treatment of systemic and cutaneous autoimmune diseases. / Raychaudhuri, Siba P; Raychaudhuri, Smriti.

In: Indian Journal of Dermatology, Vol. 54, No. 2, 01.04.2009, p. 100-109.

Research output: Contribution to journalArticle

@article{df038b37d95e46fbb5419cc947f63a75,
title = "Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases",
abstract = "Biologics are becoming important in the treatment of systemic and cutaneous autoimmune diseases. They are designed to target specific components of immune system. As the new drugs are capable of targeting proteins in a more specific fashion, yet have lower risks of systemic side-effects, they have considerable advantages over the older immunomodulators. The development of TNF-alpha blockers in the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis have been major breakthroughs. Likewise, B-cell depletion has proved to be equally revolutionary for the treatment of lupus, pemphigus, certain vasculitides etc. But all said and done, the development of these molecules and their clinical usage are still at evolving stages. Consensus needs be formed to further categorize the clinical profiles of the patients in whom biologics are to be used in the future, given that the long-term safety profiles of these agents are very much unknown at present.",
keywords = "Anti-cytokines, B-Lymphocyte, Biologics, Immunonodulation, TCR",
author = "Raychaudhuri, {Siba P} and Smriti Raychaudhuri",
year = "2009",
month = "4",
day = "1",
doi = "10.4103/0019-5154.53175",
language = "English (US)",
volume = "54",
pages = "100--109",
journal = "Indian Journal of Dermatology",
issn = "0019-5154",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Biologics

T2 - Target-specific treatment of systemic and cutaneous autoimmune diseases

AU - Raychaudhuri, Siba P

AU - Raychaudhuri, Smriti

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Biologics are becoming important in the treatment of systemic and cutaneous autoimmune diseases. They are designed to target specific components of immune system. As the new drugs are capable of targeting proteins in a more specific fashion, yet have lower risks of systemic side-effects, they have considerable advantages over the older immunomodulators. The development of TNF-alpha blockers in the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis have been major breakthroughs. Likewise, B-cell depletion has proved to be equally revolutionary for the treatment of lupus, pemphigus, certain vasculitides etc. But all said and done, the development of these molecules and their clinical usage are still at evolving stages. Consensus needs be formed to further categorize the clinical profiles of the patients in whom biologics are to be used in the future, given that the long-term safety profiles of these agents are very much unknown at present.

AB - Biologics are becoming important in the treatment of systemic and cutaneous autoimmune diseases. They are designed to target specific components of immune system. As the new drugs are capable of targeting proteins in a more specific fashion, yet have lower risks of systemic side-effects, they have considerable advantages over the older immunomodulators. The development of TNF-alpha blockers in the treatment of psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis have been major breakthroughs. Likewise, B-cell depletion has proved to be equally revolutionary for the treatment of lupus, pemphigus, certain vasculitides etc. But all said and done, the development of these molecules and their clinical usage are still at evolving stages. Consensus needs be formed to further categorize the clinical profiles of the patients in whom biologics are to be used in the future, given that the long-term safety profiles of these agents are very much unknown at present.

KW - Anti-cytokines

KW - B-Lymphocyte

KW - Biologics

KW - Immunonodulation

KW - TCR

UR - http://www.scopus.com/inward/record.url?scp=68049132899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049132899&partnerID=8YFLogxK

U2 - 10.4103/0019-5154.53175

DO - 10.4103/0019-5154.53175

M3 - Article

VL - 54

SP - 100

EP - 109

JO - Indian Journal of Dermatology

JF - Indian Journal of Dermatology

SN - 0019-5154

IS - 2

ER -